Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Apr 5, 2011 (rev. 1)

Premium

Abbott Molecular has launched its CE-Marked Abbott HBV Sequencing test in the European Union. The test is the first sequencing-based diagnostic to be developed by Abbott, and was developed on Life Technologies' CE 3130 DNA sequencing system.

According to the company, the test identifies the DNA sequence of the hepatitis B virus polymerase gene, including all clinically relevant HBV drug resistant mutations.

This molecular diagnostic test was developed to help physicians monitor HBV infections, guide treatment decisions, and predict or discover drug resistance. It is not intended for screening blood donors, plasma, or tissue donors for HBV, or to be used as a diagnostic test to confirm the presence of HBV infection, Abbott said.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.